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Abstract
Background: Although the individual and economic disease burden of depression is particularly high for long-term
symptoms, little is known of the lifetime course of chronic depression. Most evidence derives from clinical samples,
and the diagnostic distinction between persistent depressive disorder (PDD) and non-chronic major depression
(NCMDD) is still debated. Thus, we examined characteristics of PDD among clinical vs. non-clinical cases, and the
associated disease burden at a population level.
Methods: Data were drawn from the mental health module of the German Health Interview and Examination
Survey for Adults (DEGS1-MH, 2009–2012, n = 4483) and a clinical sample of PDD inpatients at Charité – Universitätsmedizin
Berlin (2018–2019, n = 45). The DSM-5 definition of PDD was operationalized a priori to the study using interview-based
DSM-IV diagnoses of dysthymia and major depression lasting at least 2 years in both surveys. Additional depression
characteristics (depression onset, self-classified course, suicidality, comorbid mental disorders, treatment history and current
depressive symptoms [Patient Health Questionnaire-9]) were assessed. In the DEGS1-MH, health-related quality of life (Short
Form Health Survey-36, SF-36), chronic somatic conditions, number of sick days (past 12months) or days with limitations in
normal daily life activities (past 4 weeks), and health service utilization (past 12months) were compared for PDD vs. NCMDD.
Results: PDD cases from the clinical sample had a significantly earlier depression onset, a higher proportion of self-
classification as persistent course, and treatment resistance than PDD and NCMDD cases in DEGS1-MH. At a population
level, PDD cases showed worse outcomes compared with NCMDD cases in terms of somatic comorbidity, SF-36 mental
component score, and activity limitations owing to mental health problems, as well as a higher risk for outpatient mental
health care contact.
Conclusions: The distinction between PDD and NCMDD proposed for DSM-5 seems warranted. Early onset depression, self-
classification as persistent depressive course, and treatment resistance are suggested as markers of more severe and chronic
depression courses. At a population level, PDD is associated with remarkably higher individual and economic disease
burden than NCMDD, highlighting the need to improve medical recognition of chronic courses and establish specific
treatment concepts for chronic depression.
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Background
More than 300 million people globally were affected by de-
pression in 2015, reflecting an increase of about 18% since
2005 in clinical settings [1]. In terms of years lived with dis-
ability, depressive disorder is now a leading contributor to
non-fatal health loss [2]. Owing to its individual and eco-
nomic disease burden, depression has become a global core
health challenge of the twenty-first century [3–7]. Social in-
surance agencies in Germany have reported an increase in
the frequency of depression and growing health care costs
owing to working days lost, early retirement, and increased
health service provision [8, 9].
However, there are individual differences in depression
course (i.e., single episodes vs. recurrent episodes), type,
and severity. The enormous economic impact of depres-
sion on the general population seems particularly related
to its duration (i.e., long-term), rather than to its severity
[10–14]. Primary data indicate that up to 30% of depres-
sion cases have a chronic course with symptoms that last
for at least 2 years [12, 15–17]. The 12-month preva-
lence of chronic depression is 1.5% [18] and its lifetime
prevalence is 3 to 6% [16–18]. In Germany, there is a
lack of population-based information on chronic vs.
non-chronic depression courses. However, secondary
data from national health insurance companies indicate
that up to two-thirds of medical depression diagnoses
take a chronic course over at least 2 years (repeated
registration irrespective of type or severity) [19].
Furthermore, chronic depression may have an earlier
onset (before 21 years of age) [14, 20–22] and worse
outcomes than non-chronic depression, such as single or
recurrent depressive episodes with full inter-episode recov-
ery. Chronic depression is characterized by higher comor-
bidity rates [12–15, 18, 20, 22], somatic morbidity [14, 15],
suicidality [14, 20, 22], reduced somatic and psychological
well-being and health-related quality of life [12–14, 23],
lower employment rates [24], longer delays for treatment
[15], and limited effects of psychotherapeutic or psycho-
pharmacological treatment [10, 11, 13, 25–27], all of which
indicate its enormous direct and indirect costs.
However, comparisons of the characteristics, prevalence,
and disease burden of chronic vs. non-chronic depression
is hampered by two facts: most knowledge derives from
clinical samples [15] and prevalence estimates differ, be-
cause a generally accepted definition of chronic depression
was lacking until the American Psychiatric Association in
2013 decided to include a new depressive subtype, persist-
ent depressive disorder (PDD), in the latest version of the
Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition (DSM-5) [28, 29]. PDD is defined as depres-
sion that persists for at least 2 years. The PDD subtype is
thus a combination of the DSM-IV diagnoses of (lasting)
major depressive disorder (MDD) and dysthymic disorder
(DD). However, even the new PDD diagnostic category
does not consider additional lifetime information [25].
Thus, little is known about chronic depression during the
lifespan (e.g., regarding early vs. late onset depression).
Furthermore, the DSM-5 PDD diagnosis relies predomin-
antly on clinical data and the concept of PDD has been
criticized [30], as its reliability has not been formally ex-
amined [31]. However, some researchers still argue for a
diagnostic distinction between chronic and non-chronic
forms of MDD [32].
In this study, we aimed to comparatively analyze and dif-
ferentiate characteristics of PDD vs. non-chronic depression
courses during the lifetime using population-based data
from the German health monitoring program at the Robert
Koch Institute and a clinical sample from Charité – Univer-
sitätsmedizin Berlin. We hoped to extend the knowledge of
chronic depression beyond the data from clinical samples,
provide frequency information at a population level, and
quantify the individual and economic disease burden of
chronic depression for the general population in Germany.
The findings from clinical studies suggest that both the
indirect costs (e.g., to health-related quality of life or sick
(leave) days) and the direct costs of health service utilization
and treatment resistance are much higher for PDD cases
than for non-chronic cases.
The study objectives were 1) the classification of
chronic vs. non-chronic depression courses at a popula-
tion level, 2) the identification of PDD characteristics in
a clinical vs. population-based sample, and 3) the com-
parison of PDD vs. non-chronic MDD (NCMDD) in
terms of associations with health-related correlates at a
population level.
Methods
Data basis and depression assessment
Data for the nationwide representative analyses were
drawn from the first wave of the German Health Interview
and Examination Survey for Adults (DEGS1, field work
2008–2011, n = 7115) and its mental health module
(DEGS1-MH, field work 2009–2012, n = 4483), which in-
cluded 18- to 79-year-old participants from statutory as
well as private health insurances based on a two-stage
clustered random sampling procedure (step 1: random
sampling of study locations from all municipal communi-
ties; step 2: random sampling of participants from the
population-registries in each sampled study location). The
design and methods are described in detail elsewhere [33–
35]. DEGS1 and DEGS1-MH were part of the German
health monitoring program and provided data about the
health of the non-institutionalized population in Germany
based on self-rated questionnaires and a standardized
computer-assisted Interview conducted by study physi-
cians (CAPI). Mental disorders, including MDD and DD,
were assessed by trained interviewers based on the World
Health Organization Composite International Diagnostic
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Interview (CIDI). The CIDI is a standardized fully struc-
tured computer-assisted clinical face-to-face interview and
is an internationally established measure of mental disor-
ders [36–38]. A modified German version of the CIDI was
used in DEGS1-MH [33] to assess mental disorders ac-
cording to the DSM-IV-TR diagnostic criteria [39]. The
CIDI provides lifetime information about symptoms (e.g.,
age of onset, recurrence and duration of episodes) that
permits analysis of the course of depression over the life-
span. After participants with missing information on
affective disorders were excluded (n = 75), the final study
sample was n = 4408.
Data were also obtained from a clinical sample re-
cruited at the Charité – Universitätsmedizin Berlin (n =
60). Patients with a professional diagnosis of PDD ac-
cording to DSM-5 [28] were treated for 12 weeks with a
specialized chronic depression intervention: the Cogni-
tive Behavioral Analysis System of Psychotherapy
(CBASP; [27, 40]). Patients were either directly referred
from the outpatient clinic of the Charité, from inpatient
wards of other hospitals from all parts of Germany, or
from outpatient psychiatrists. Treatment was reimbursed
by statutory health insurances. Exclusion criteria for the
inpatient CBASP were a history of psychotic episodes,
bipolar I or II disorders, comorbid substance depend-
ence with less than 3 months of abstinence, severe forms
of autism, and organic mental disorders. All patients
treated at the ward from 2013 to 2018 were invited for a
subsequent follow-up interview for the purpose of the
present study. These interviews were conducted from
October 2018 to March 2019 to collect lifetime informa-
tion on course and type of depression and comorbid
mental disorders using the Structured Clinical Interview
for DSM-IV (SCID I; [41]) and self-rated questionnaires.
To allow comparison with the epidemiological sample,
additional questions based on the CIDI depression sec-
tion were included. The final clinical study sample com-
prised n = 45 patients, aged 24–66 years.
Definition and operationalization of (non-)chronic
depression
For this study, the definition of chronic depression was
based on the DSM-5 PDD diagnosis and drawn from the
DSM-IV-based diagnoses of MDD or DD derived from
the SCID I or CIDI. According to DSM-IV, MDD diagno-
sis requires the persistence of at least five out of nine
depressive symptoms on nearly every day for 2 weeks or
longer, of which at least one is depressed mood or
decreased interest/pleasure (criterion A). Furthermore,
clinically significant distress and impairment associated
with these symptoms are necessary (criterion C). MDD
exclusion criteria include lifetime manic/hypomanic epi-
sodes (criterion B) and depressive symptoms solely attrib-
utable to the direct physiological effects of a substance or
a general medical condition (criterion D) or attributable to
grief (criterion E). DD diagnosis requires depressed mood
for most of the day and for at least 2 years (criterion A),
and at least two out of six depression symptoms (criterion
B). During the 2 years, the total recovery time should not
have exceeded more than 2months (criterion C) and the
symptoms should have caused clinically significant distress
or impairment (criterion H). Exclusion criteria include
manic/hypomanic episodes (criterion E), symptoms owing
to the direct physiological effects of a substance or a gen-
eral medical condition (criterion G), or symptoms occur-
ring during the course of a psychotic disorder (criterion
F). Furthermore, DSM-IV DD diagnosis requires the ab-
sence of a major depressive episode during the first 2 years
of occurrence (criterion D). However, DSM-5 no longer
includes this criterion for PDD diagnosis, and MDD cri-
teria may be continuously present for 2 years.
Thus, subjects with lifetime or 12-month MDD ac-
cording to CIDI or SCID I who also report a lifetime
maximum episode duration of at least 104 weeks, as well
as subjects (concurrently) fulfilling the DD diagnostic
criteria (irrespective of DSM-IV criterion D), were classi-
fied as lifetime PDD cases. The remaining MDD cases
were categorized as non-chronic cases (NCMDD). The
grouping of PDD and NCMDD was carried out a priori
to the study. Cases with missing responses for maximum
episode duration and missing information on diagnostic
criteria of DD have been omitted. In the clinical sample,
health professional-diagnosed PDD was validated via
SCID I for all patients.
Depression characteristics
Age of depression onset and the number of depressive
episodes were assessed in both diagnostic interviews.
History of suicidality was also assessed in both surveys
based on CIDI questions about thoughts of death or sui-
cide, suicide plans, or attempted suicide.
Subjects of DEGS1-MH and patients of the clinical
sample rated their course of depression based on CIDI
depression section diagram on the following categories:
single episode (remitted), single episode (acute), recur-
ring episodes, single episode with chronic course, per-
sistent depressive course, double depression, or other.
MDD symptoms according to DSM-IV were assessed
using the German version of the internationally established
Patient Health Questionnaire (PHQ-9). The PHQ-9 con-
sists of nine items assessing the presence and frequency of
depressive symptoms during the past 2 weeks. Summed
scores ≥10 indicate current depressive symptoms [42, 43].
The number of comorbid mental disorders (lifetime)
was categorized as none, one, and at least two of the
CIDI- or SCID I-based diagnoses of mental disorders
during the lifetime. As some mental disorders were in-
cluded in the exclusion criteria for the clinical sample,
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the following comorbid diagnoses were assessed: panic
disorder, agoraphobia, generalized anxiety disorder, social
phobia, specific phobias, obsessive–compulsive disorder,
posttraumatic stress disorder, pain and somatoform disor-
ders, substance abuse and dependence (excluding nico-
tine), anorexia nervosa, bulimia nervosa, and binge eating
disorder.
Self-reported mental health treatment during the life-
time was assessed based on the CIDI questions in both
DEGS1-MH and the clinical sample. The number of
antidepressant treatments and the number of psycho-
therapies were each categorized as none, one, and at
least two treatments. Treatment resistance was defined
for cases with at least two reported antidepressant treat-
ments, approaching the definition of Thase and Rush
(medication resistance to two or more adequate trials of
antidepressants) [44].
Health-related correlates
Several health-related correlates were assessed in DEGS1-
MH: self-rated health (dichotomized into fair/poor vs.
good/very good/excellent) and health-related quality of life
(past 4 weeks) were assessed using the German version of
the Short Form Health Survey-36 (SF-36) version 2 [45,
46]). The physical component score (PCS) and the mental
component score (MCS) were used as total scales with a
mean value of 50 and a standard deviation of 10 (higher
values indicate better health-related quality of life). The
number of days with limitations in normal daily life activ-
ities owing to physical vs. mental health problems (includ-
ing limitations owing to substance use) during the past 4
weeks were also assessed [see 23]. The self-reported num-
ber of sick days during the past 12months was assessed in
DEGS1 (irrespective of occupational status), as well as
self-reported information on health service use during the
past 12months (number of outpatient physician visits,
outpatient psychiatric or psychotherapeutic contacts, and
number of nights in hospital). The number of chronic
somatic conditions reported in DEGS1 was classified as
none, one, and at least two of the following somatic condi-
tions [see 47]: myocardial infarction (lifetime), chronic
heart failure (lifetime), stroke (lifetime), osteoarthritis (life-
time), rheumatoid arthritis (past 12months), osteoporosis
(lifetime), gout (past 12months), bronchial asthma (past
12months), cirrhosis of the liver (lifetime), hepatitis (past
12months), gastric-duodenal ulcer (past 12months), can-
cer (lifetime), Parkinson’s disease (lifetime), epilepsy (past
12months), hypertension (past 12months), dyslipidemia
(past 12months), renal failure (lifetime), and inflammatory
bowel disease (past 12months).
Other measures
Sociodemographic variables included sex, age, marital
status, and educational level. Age was assessed in years
at the time of the clinical follow-up as well as of the
DEGS1 mental health module assessment and catego-
rized into age groups (18–34, 35–49, 50–64, and 65–79
years). Marital status was dichotomized into married
and living with partner vs. married and not living with
partner/single/never been married/divorced/widowed.
The Comparative Analysis of Social Mobility in Indus-
trial Nations (CASMIN) scale was used to classify
responses on educational level into low, medium, and
high. In DEGS1-MH, structural social support was
assessed using the Oslo-3 Social Support Scale [48].
Statistical analysis
Frequency and mean estimates of the sample characteris-
tics are reported with 95% confidence intervals (95% CI).
At a population level, prevalence estimates for lifetime
MDD and DD are reported. Conditional frequencies for
chronic vs. non-chronic courses among lifetime MDD cases
are reported. Prevalence estimates for PDD and NCMDD
could not be provided owing to many missing responses
for self-reported maximum episode duration, resulting in a
high proportion of MDD with unknown chronicity.
Frequency and mean estimates for depression character-
istics are reported with 95% CI for PDD cases in the clin-
ical sample and for PDD and NCMDD cases in the
population-based sample. The significance (p < .01) of dif-
ferences between the clinical sample and the DEGS1-MH
sample was indicated by non-overlapping 95% Cis [47]
and sizes of significant effects for independent groups with
different sample size are indicated by Cohen’s d (small =
0.2, medium= 0.5, large = 0.8). Statistical significance of
differences between PDD and NCMDD characteristics in
DEGS1-MH were evaluated using the Rao–Scott chi-
square test for categorical variables, and the Wilcoxon–
Mann–Whitney test for continuous variables, using a two-
sided significance level of 0.05.
Health-related correlates are shown for DEGS1-MH
PDD vs. NCMDD cases with 95% CI, to enable the com-
parison of the associated individual and economic disease
burden at a population level. Effect estimates for health-
related correlates in cases with PDD vs. NCMDD were
based on logistic, linear, negative binomial, or zero-inflated
negative binomial regression models, including health-
related correlates as dependent variables and depression
course (PDD vs. NCMDD) as the independent variable (ref-
erence: NCMDD). All analyses were adjusted for sex, age
group, educational level, marital status, social support,
chronic somatic conditions (except for analysis of the num-
ber of chronic somatic conditions as an outcome variable),
and PCS (except for analysis of PCS as an outcome
variable) [see 49]. The results of the unadjusted regression
analyses are included as supplementary data (see Add-
itional file 1) and only described if divergent. Statistical
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significance was evaluated based on a two-sided significance
level of 0.05.
All statistical analyses were performed using Stata 15.1
(StataCorp, College Station, Texas, USA). For DEGS1-MH,
all analyses were performed using the Stata survey design
procedures to account for clustering and weighting of the
study sample. Thus, survey-specific weighting factors were
used to adjust the sample to the demographic distribution
of the population in Germany as on 31st December, 2010,
regarding sex, age, educational status, federal state, nation-
ality, and the probability of participation in the mental
health module subsequent to the core survey [33, 50].
In addition, we calculated post-hoc power analyses to
test for appropriate test power based on the present sam-
ple sizes.
Results
Sample characteristics
Sample characteristics of the clinical sample and
DEGS1-MH sample are shown in Table 1. The DEGS1-
MH sample was comparable to the clinical sample on
age and sex, except for the proportion of participants
aged 50–64 years (higher in the clinical sample) and 65–
79 years (higher in DEGS1-MH participants). Clinical
sample patients more frequently lived alone (88.9% vs.
39.2%) and demonstrated a significantly higher educa-
tional level than the DEGS1-MH sample (as indicated by
non-overlapping 95% Cis).
Chronic depression at a population level
Among cases with lifetime MDD in DEGS1-MH (14.5%),
18.2% reported a maximum episode duration of at least 2
years, and 15.4% fulfilled the diagnostic criteria of concur-
rent DD (without considering criterion D). Overall, 36.5%
of cases with a lifetime CIDI diagnosis of MDD were clas-
sified as chronic MDD cases; the remaining 63.5% were
categorized as NCMDD cases. In addition to chronic
MDD, PDD also comprised subjects with solely lifetime
DD (1.3%, without considering criterion D).
Characteristics of chronic depression in a clinical sample
and at a population level
PDD cases from the clinical sample had a significantly
earlier disease onset than cases with PDD and NCMDD
in DEGS1-MH (age of disorder onset < 21 years: 73.3%
vs. 24.7% vs. 32.2%, see Table 2). Suicidality (thoughts of
death/suicide, or having suicide plans/attempts) was re-
ported more often by PDD cases in the clinical sample
than by PDD or NCMDD cases in the DEGS1-MH sam-
ple (95.5% vs. 86.4% vs. 86.2%), as was attempted suicide
Table 1 Sample characteristics of the clinical and the population-based sample
Clinical sample1
(n = 45)
DEGS1-MH2
(n = 4408)
Cohen’s d
Sex, % (95% CI)
Male 53.3 (37.8–66.7) 49.1 (47.1–51.0) 0.84
Female 46.7 (33.3–62.2) 50.9 (49.0–52.9) 0.84
Age, mean (95% CI) 47.1 (43.6–50.6) 48.0 (47.4–48.6) 0.18
Age group (years), % (95% CI)
18–34 22.2 (12.1–37.2) 24.8 (23.1–26.5) 0.61
35–49 24.4 (13.8–39.6) 29.2 (27.5–30.9) 1.07
50–64 51.1 (36.3–65.8) 25.4 (24.0–26.9) 5.83
65–79 2.2 (0.3–15.1) 20.7 (19.4–22.0) 4.53
Marital status3, % (95% CI)
Married and living with partner 11.1 (2.2–20.0) 60.8 (58.5–63.2) 26.87
Married and not living with partner/Single/Divorced/Widowed 88.9 (80.0–97.8) 39.2 (36.9–41.6) 10.18
Educational level4, % (95% CI)
Low 2.3 (0.0–6.8) 35.0 (32.6–37.6) 6.90
Medium 36.4 (22.7–52.3) 50.8 (48.7–52.9) 2.89
High 61.4 (47.7–45.0) 14.2 (12.6–16.0) 13.51
CI confidence interval, CIDI Composite International Diagnostic Interview, Cohen’s d effect size computed for groups with different sample size, by adjusting the
calculation of the pooled standard deviation with weights for the sample sizes
1Clinical Sample at Charité - Universitätsmedizin Berlin: 2018–2019; n = 45 re-participants based on n = 60 patients who participated in inpatient treatment with
the Cognitive Behavioral Analysis System of Psychotherapy (CBASP [40]), age range: 24–66 years
2German Health Interview and Examination Survey for Adults, mental health module (DEGS1-MH): 2009–2012, weighted for population structure as of 31st
December 2010; age range: 18–79 years; n = 4408 with full CIDI mood disorders section
3In DEGS1-MH, n = 32 subjects did not provide information on marital status
4Categorization according to the Comparative Analysis of Social Mobility in Industrial Nations (CASMIN) scale. There were missing values for n = 1 subject in the
clinical sample and n = 17 participants in the DEGS1-MH sample
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(36.4% vs. 16.2% vs. 11.7%), but the significance of these dif-
ferences remains unclear with one exception: the propor-
tion of PDD patients in the clinical sample that attempted
suicide was more than three times greater than the propor-
tion of NCMDD cases in DEGS1-MH. Regarding self-
reported depression course, PDD cases differed significantly
from NCMDD cases in DEGS1-MH (p < 0.001). Both PDD
groups showed significantly higher rates of a chronic course
of a single episode compared with NCMDD cases (25.0 and
24.3% vs. 5.9%). Furthermore, a significantly higher propor-
tion of clinical PDD patients showed a persistent depressive
course compared with PDD and NCMDD DEGS1-MH
cases (50.0% vs. 24.6% vs. 2.0%), and a smaller frequency of
recurring episodes (2.3% vs. 20.9% vs. 55.1%; significant dif-
ference only for clinical PDD patients compared with
NCMDD cases). Accordingly, cases with PDD in DEGS1-
MH reported a significantly higher mean number of epi-
sodes in total (13.7) compared with both clinical PDD
Table 2 Characteristics of cases with (non-)chronic depression during the lifetime in clinical and population-based samples
Cases with PDD in
clinical sample1
(n = 45)
Cases with PDD
in DEGS1-MH2
(n = 179)
Cases with NCMDD
in DEGS1-MH
(n = 205)
p-value5
Age of disorder onset < 21 years3, % (95% CI) 73.3 (58.0–84.5) 24.7 (18.2–32.6) 32.2 (23.8–41.9) 0.192
Thoughts of death/suicide, or suicide
plans/attempts3, % (95% CI)
95.5 (82.8–98.9) 86.4 (78.7–91.6) 86.2 (77.6–91.8) 0.960
Attempted suicide3, % (95% CI) 36.4 (23.2–52.0) 16.2 (9.2–26.8) 11.7 (6.9–19.3) 0.393
Self-reported depression course3, % (95% CI) < 0.001
Single episode, remitted – 2.3 (0.9–5.4) 17.7 (10.4–28.3)
Single episode, acute – 5.7 (2.7–11.7) 4.0 (1.6–9.9)
Recurring episodes 2.3 (0.3–15.5) 20.9 (14.4–29.3) 55.1 (45.0–64.8)
Single episode, chronic course 25.0 (14.1–40.4) 24.3 (14.9–36.9) 5.9 (3.1–10.9)
Persistent depressive course 50.0 (35.1–64.9) 24.6 (16.9–34.4) 2.0 (0.5–7.9)
Double depression 15.9 (7.5–30.5) 19.3 (12.4–28.8) 11.9 (6.4–21.3)
Other 6.8 (2.1–19.9) 2.9 (0.9–9.4) 3.5 (1.1–9.9)
No. of episodes3, mean (95% CI) 2.8 (1.9–3.6) 13.7 (8.4–19.0) 7.4 (5.1–9.7) < 0.001
No. of comorbid mental disorders (lifetime)4, % (95% CI) 0.071
0 46.7 (32.2–61.7) 28.7 (20.8–38.2) 36.9 (28.0–46.7)
1 33.3 (20.8–48.8) 28.9 (21.7–37.5) 37.4 (29.0–46.8)
2 13.3 (5.9–27.3) 31.0 (21.8–42.0) 16.4 (10.5–24.8)
≥ 3 6.7 (2.1–19.4) 11.4 (6.2–20.1) 9.3 (5.0–16.6)
Current depressive symptoms (PHQ-9≥ 10), % (95% CI) 66.7 (51.2–79.2) 44.9 (35.1–55.1) 18.6 (12.1–27.5) < 0.001
No. of psychotherapeutic treatments (lifetime) 0.271
0 – 87.2 (76.3–93.5) 92.6 (86.6–96.0)
1 9.1 (2.8–2.6) 10.1 (4.7–20.3) 6.5 (3.3–12.6)
≥ 2 90.9 (74.1–97.2) 2.7 (1.1–6.7) 0.9 (0.3–2.4)
No. of antidepressant medications (lifetime) 0.674
0 2.4 (0.3–16.2) 79.5 (71.7–85.6) 75.1 (66.2–82.3)
1 16.7 (7.9–31.8) 11.4 (7.4–17.1) 12.7 (7.8–20.1)
≥ 2 81.0 (65.6–90.5) 9.1 (5.1–15.9) 12.2 (7.0–20.3)
CI confidence interval, PDD persistent depressive disorder, NCMDD non-chronic major depressive disorder, SCID I Structured Clinical Interview for DSM-IV, CIDI
Composite International Diagnostic Interview
1Clinical Sample at Charité - Universitätsmedizin Berlin: 2018–2019; n = 45 re-participants based on n = 60 patients who participated in inpatient treatment with
the Cognitive Behavioral Analysis System of Psychotherapy (CBASP [40]), age range: 24–66 years
2German Health Interview and Examination Survey for Adults, mental health module (DEGS1-MH): 2009–2012, weighted for population structure as of 31st
December 2010; age range: 18–79 years; n = 4408 with full CIDI mood disorders section
3Based on CIDI
4Based on SCID I or CIDI diagnoses of panic disorder, agoraphobia, generalized anxiety disorder, social phobia, specific phobias, obsessive–compulsive disorder,
posttraumatic stress disorder, pain and somatoform disorders, substance abuse and dependence (excluding nicotine), anorexia nervosa, bulimia nervosa, and
binge eating disorder
5p-value based on Rao–Scott chi-square test for categorical variables and based on Wilcoxon–Mann–Whitney test for continuous variables in DEGS1-MH. Bold type
indicates significant differences between subjects with PDD and NCMDD in DEGS1-MH (local significance level α = 0.01)
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patients (2.8) and NCMDD cases in DEGS1-MH (7.4, p <
0.001). Comorbid mental disorders seemed to be more pro-
nounced among cases with PDD and NCMDD in DEGS1-
MH compared with the clinical sample, but the significance
of these differences remains unclear. There was a trend for
higher comorbidity among PDD cases than among
NCMDD cases in DEGS1-MH (p = 0.071). The prevalence
of current depressive symptoms was highest among the
clinical PDD patients (PHQ-9 ≥ 10: 66.7%), and significantly
higher among PDD cases compared with NCMDD cases in
DEGS1-MH (44.9% vs. 18.6%, p < 0.001). Furthermore,
clinical PDD cases showed a significantly higher treatment
resistance than PDD and NCMDD cases in DEGS1-MH, in
terms of the proportion of cases reporting at least two psy-
chotherapeutic treatments (90.9% vs. 2.7% vs. 0.9%) or anti-
depressant medications (81.0% vs. 9.1% vs. 12.2%) during
the lifetime. Most PDD and NCMDD cases in DEGS1-MH
reported no psychotherapeutic treatment (87.2 and 92.6%)
or antidepressant medication (79.5 and 75.1%).
Health-related correlates of (non-)chronic depression at a
population level
The associations of PDD vs. NCMDD with health-related
correlates based on DEGS1-MH are shown in Tables 3
and 4. The risk of experiencing fair or poor self-rated
health was significantly higher among PDD cases (36.8%)
than among NCMDD cases (20.4%, odds ratio [OR] = 2.0,
p = 0.041). Mean health-related quality of life (past 4 weeks)
was lower among PDD cases for PCS (47.1 vs. 50.7, signifi-
cant only for crude effect estimates, see Additional file 1)
and MCS (34.5 vs. 43.8, β = − 8.2, p < 0.001). Accordingly,
the mean number of days with activity limitations (past 4
weeks) owing to mental health problems was higher for
PDD than for NCMDD (5.4 vs. 2.4, incidence rate ratio
[IRR] = 2.6, p < 0.001). There was also a trend for more re-
ported limitation days owing to physical health problems
for PDD compared with NCMDD cases (5.3 vs. 3.1, IRR =
1.4, p = 0.091). There was also a higher risk of sick days
during the past 12months for PDD cases (34.2 vs. 14.8),
but this was only significant in the unadjusted analysis (see
Additional file 1). Indicators of health service use during
the past 12months showed higher utilization rates for PDD
than for NCMDD cases for the mean number of outpatient
psychiatric or psychotherapeutic contacts (5.7 vs. 1.7, IRR =
2.7, p = 0.006). There was also a trend for PDD cases to re-
port a higher mean number of nights in hospital compared
with NCMDD cases (3.9 vs. 0.9, IRR = 1.9, p = 0.065). The
mean number of outpatient physician visits (4.3 vs. 3.6) was
Table 3 Health-related correlates in cases with PDD vs. NCMDD during the lifetime at a population level1
PDD
(n = 179)
NCMDD
(n = 205)
Fair/poor self-rated health, % (95% CI) 36.8 (28.8–45.6) 20.4 (13.8–29.0)
Health-related quality of life (past 4 weeks), mean (95% CI)
Physical component score 47.1 (44.9–49.4) 50.7 (48.8–52.7)
Mental component score 34.5 (32.2–36.8) 43.8 (41.7–45.9)
No. of days with activity limitations (past 4 weeks), mean (95% CI)
Owing to mental health problems 5.4 (4.1–6.7) 2.4 (1.2–3.6)
Owing to physical health problems 5.3 (3.9–6.7) 3.1 (1.9–4.2)
No. of sick days (past 12 months), mean (95% CI) 34.2 (17.6–50.8) 14.8 (9.9–19.7)
No. of outpatient physician visits (past 12 months), mean (95% CI) 4.3 (3.4–5.2) 3.6 (2.9–4.2)
No. of outpatient psychiatric or psychotherapeutic contacts
(past 12 months), mean (95% CI)
5.7 (2.1–9.4) 1.7 (0.7–2.7)
No. of hospital nights (past 12 months), mean (95% CI) 3.9 (1.2–6.6) 0.9 (0.5–1.3)
No. of chronic somatic conditions2, % (95% CI)
0 42.8 (33.7–52.5) 63.9 (53.7–72.9)
1 31.0 (22.9–40.4) 20.6 (13.6–30.0)
2+ 26.2 (19.6–34.1) 15.6 (10.0–23.5)
CI confidence interval, PDD persistent depressive disorder, NCMDD non-chronic major depressive disorder, CIDI Composite International Diagnostic Interview
1German Health Interview and Examination Survey for Adults, mental health module (DEGS1-MH): 2009–2012, weighted for population structure as of 31st
December 2010; age range: 18–79 years; n = 4408 with full CIDI mood disorders section
2Myocardial infarction (lifetime), chronic heart failure (lifetime), stroke (lifetime), osteoarthritis (lifetime), rheumatoid arthritis (past 12 months), osteoporosis
(lifetime), gout (past 12months), bronchial asthma (past 12 months), cirrhosis of the liver (lifetime), hepatitis (past 12 months), gastric-duodenal ulcer (past 12
months), cancer (lifetime), Parkinson’s disease (lifetime), epilepsy (past 12 months), hypertension (past 12 months), dyslipidemia (past 12 months), renal failure
(lifetime), and inflammatory bowel disease (12 months)
Bold type indicates significant associations between depression course (PDD vs. NCMDD) and health-related correlates (at local significance level α = 0.05, resulting
from multiple (continuous outcome), multiple negative binomial (dichotomous outcome) or multinomial (multinomial outcome) regression analyses; see Table 4
for detailed statistical parameters)
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only significantly higher for PDD cases in the unadjusted
analysis (see Additional file 1). Furthermore, somatic co-
morbidity was significantly higher for PDD vs. non-chronic
cases. The risk of having one chronic condition (31.0% vs.
20.6%, relative risk ratio [RRR] = 2.8, p = 0.008) or at least
two comorbid conditions (26.2% vs. 15.6%, RRR = 3.2, p =
0.004) was approximately 3-fold for PDD. In contrast, most
NCMDD cases (63.9%) had no somatic comorbidity at all
(vs. 42.8% of PDD cases).
Post-hoc power analyses
Results from post-hoc power analyses with the help of
G*Power 3 [51] suggest that that the present sample size
of n = 429 individuals was sufficient for the detection of
moderate effects (ω = 0.30) within a chi-square goodness-
of-fit test comparing PDD vs. NCMDD in clinical and
population-based samples for each health-related correlate
and an error probability of α = 0.05, at the power level of
1.00 (see Table 2). Moreover, results from post-hoc power
calculation suggest that the present sample size of n = 285
individuals was sufficient for the detection of moderate ef-
fects (f2 = 0.15) within a multiple regression design con-
taining five predictors (PDD vs. NCMDD, age, sex, marital
status, educational level) on each health-related correlate
in a population-based sample, with an error probability of
α = 0.05 and at the power level of 1.00 (see Table 4).
Discussion
Based on a nationally representative sample of the general
adult population in Germany, more than one-third (36.5%)
of all subjects fulfilling MDD criteria showed a chronic de-
pression course with maximum episode duration of at least
2 years and/or concurrent dysthymia at least once during
the lifetime. This rate is slightly higher than previous inter-
national frequency estimates, which reported a chronic
course for only 21 to 30% of depressed cases [12, 15–17].
This inconsistency can be explained by different definitions
of chronic depression: previous prevalence based solely on
episode duration, without considering MDD cases with
double depression (i.e., MDD and DD).
More severe PDD cases in the health care system
Overall, our estimated frequency for DEGS1-MH cases
with MDD that had a chronic course during the lifetime
(36.5%) was much lower than the proportion reported
from national health insurance data (65%) [19]. However,
previous findings show that among cases with CIDI-based
MDD, 65.4% did not report any health service use for
Table 4 Effect estimates for health-related correlates in cases of PDD vs. NCMDD (ref.) during the lifetime1
Effect estimate
(95% CI)
p-value
Fair/poor self-rated health OR 2.0 (1.0–3.9) 0.041
Health-related quality of life (past 4 weeks)
Physical component score β −1.2 (-3.9 – -1.5) 0.374
Mental component score β −8.2 (-11.5 – -4.9) < 0.001
No. of days with activity limitations (past 4 weeks)
Owing to mental health problems IRR 2.6 (1.6–4.3) < 0.001
Owing to physical health problems IRR 1.4 (0.9–2.1) 0.091
No. of sick days (past 12 months) IRR 1.3 (0.9–1.8) 0.193
No. of outpatient physician contacts (past 12 months) IRR 1.0 (0.8–1.3) 0.847
No. of outpatient psychiatric/psychotherapeutic contacts
(past 12 months)
IRR 2.7 (1.3–5.4) 0.006
No. of hospital nights (past 12 months) IRR 1.9 (1.0–3.8) 0.065
No. of chronic somatic conditions
0 ref.
1 RRR 2.8 (1.3–5.8) 0.008
2+ RRR 3.2 (1.4–7.0) 0.004
Regression models include health-related correlates as dependent variables and depression course (PDD vs. NCMDD) as the independent variable (reference:
NCMDD). All analyses were adjusted for sex, age group, educational level, marital status, social support, chronic somatic conditions (except for analysis of the no.
of chronic somatic conditions as an outcome variable), and PCS (except for analysis of PCS as an outcome variable). OR: Odds ratio from logistic regression; β: β
coefficient from linear model; IRR: incidence rate ratio from negative binomial regression or zero-inflated negative binomial regression; RRR: relative risk ratio from
multinomial logistic regression; p-value for testing the effect of depression course (test for OR/IRR/RRR = 1 or β = 0)
CI confidence interval, PDD persistent depressive disorder, NCMDD non-chronic major depressive disorder, PCS physical component score, CIDI Composite
International Diagnostic Interview
1German Health Interview and Examination Survey for Adults, mental health module (DEGS1-MH): 2009–2012, weighted for population structure as of 12/31/2010;
age range: 18–79; n = 4408 with full CIDI mood disorders section
Bold type indicates significant associations between depression course (PDD vs. NCMDD) and health-related correlates (at local significance level α = 0.05, resulting
from multiple (continuous outcome), multiple negative binomial (dichotomous outcome) or multinomial (multinomial outcome) regression analyses)
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mental health problems [52]; and service use increased
with depression severity [52]. Thus, particularly severe
(and chronic) depression cases may eventually access the
health care system, leading to higher proportions of
chronic depression courses based on health insurance data
[see 19] compared with frequency estimates for interview-
based MDD cases at a population level.
Consequently, our comparisons of depression character-
istics indicate that PDD cases in the health care system
are more severely affected, since clinical sample PDD pa-
tients showed a pronounced long-term duration owing to
earlier onset (73.3% vs. 24.7% with age onset ≤21 years)
and significantly higher rates of treatment resistance
(81.0% vs. 9.1% reported at least two antidepressant medi-
cation trials) compared with interview-defined PDD cases
at a population level, as well as a higher proportion of self-
classified persistence of depressive course. Furthermore,
the prevalence of attempted suicide during lifetime was
higher among clinical PDD patients as compared to the
DEGS1-MH PDD cases (but nonsignificant) and more
than three times higher than among NCMDD cases.
Considering the existing literature, our results are in
line with clinical findings. For instance, lifetime preva-
lence of treatment resistance for depression was 81.8%
in patients with long-term depression vs. 60.7% in
patients with depression lasting less than 2 years [14]. In
terms of inpatient treatment, a lifetime prevalence of
24.1% for hospitalization owing to mental health prob-
lems has been reported for PDD patients compared to
12.1% for non-PDD patients [17]. Furthermore, the aver-
age duration of past inpatient treatment is longer for
PDD cases [53]. Patients with PDD also have higher
rates of suicidal attempts and suicidal thoughts and are
more likely to have a higher frequency of treatment ap-
proaches in general and a longer disorder duration [22].
Early depression onset seems a particular marker of a
more severe PDD course: 73% of our clinical PDD pa-
tients showed an early onset, whereas the proportion
was much lower among interview-defined PDD cases in
DEGS1-MH (24.7%); and there was no significant differ-
ence between PDD and NCMDD cases at a population
level. Similarly, international findings are heterogeneous:
one meta-analysis found a significant relationship be-
tween early onset of depression and chronicity of the
disorder [54]. However, in a recent review of 17 studies
directly comparing age of onset in PDD vs. non-PDD
cases, half the studies reported earlier onset for chronic
vs. non-chronic depression whereas the other half re-
ported no difference [22].
Recent reviews found that patients with PDD more
often have psychiatric comorbidities than those with
non-PDD, particularly personality disorders but also axis
I and somatic comorbidities [22]. However, differences
between PDD and NCMDD cases in DEGS1-MH have
only been observed by trend, and our clinical sample of
PDD patients demonstrated even less comorbidity than
interview-defined cases. This may be related to differ-
ences in the diagnostic tools (SCID I vs. CIDI). Add-
itionally, personality disorders, which account for a large
proportion of comorbidities in the reviews, were not
assessed in both samples. However, interpersonal prob-
lems as indicated by the social functioning subscale of
the SF-36 were significantly reduced among PDD cases
as compared to NCMDD cases in DEGS1-MH (post hoc
sensitivity analysis; PDD: M = 61.47, 95%CI = 55.89–
67.05; NCMDD: M = 76.77, 95%CI = 72.67–80.86). Con-
sequently, only minor and non-significant differences in
mental comorbidity have been observed between
interview-defined PDD and NCMDD cases.
Higher disease burden for chronic vs. non-chronic
depression
The comparison of interview-defined cases of PDD vs.
NCMDD at a population level highlighted that several
health-related correlates indicate higher individual and
economic disease burden for chronic depression courses.
On the individual level, there was a remarkably higher
prevalence of current depressive symptoms (as assessed by
PHQ-9) among PDD cases than among NCMDD cases, as
well as a higher mean number of depressive episodes (irre-
spective of episode severity or duration). Furthermore,
higher levels of psychological and somatic comorbidity are
in line with international findings on higher comorbidity
rates [12, 14, 15, 18, 20, 22] and somatic morbidity [14, 15]
for chronic depression courses. The present outcomes of
worse self-rated health and reduced health-related quality
of life for the MCS correspond to previous findings of re-
duced psychological well-being and health-related quality
of life for individuals with chronic depression [12–14, 23].
Accordingly, chronic depression is associated with higher
indirect economic costs: PDD cases showed a higher risk of
experiencing limitation days owing to mental health prob-
lems than non-chronic cases. Our findings of higher rates
of outpatient mental health care utilization and the trend
for a higher mean number of nights in hospital also indicate
higher direct costs for the national economy and corres-
pond to previous research findings [55].
Public health implications and future perspectives
Considering the growing frequency of depression and
health care costs in Germany owing to working days lost,
early retirement, and health service provision [8, 56–58],
our data strongly support the relevance of PDD as a spe-
cific course of depressive disorders. As long-term PDD is
often associated with higher treatment resistance [59]
there is a chance that if an early and tailored treatment of
PDD and its specific psychopathological characteristics
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(e.g. CBASP) is carried out, a positive shift towards a more
positive course of the disease can be achieved.
However, self-reported utilization rates [see 52] corres-
pond with reported international treatment gaps for men-
tal disorders in general [3, 4, 6, 7]: most Germans with
acute depression do not access mental health care. In
addition, previous results indicate more frequent help-
seeking with higher education [60]. The characteristics of
our clinical sample also suggest that in particular PDD
cases with lower educational levels do not seek help or re-
ceive (specialized) treatment: While international findings
show that PDD is associated with low socioeconomic sta-
tus [61], PDD cases in our clinical sample had a signifi-
cantly higher education as compared to the general
population (DEGS1-MH participants). This is important,
as it raises the question of whether more educated pa-
tients are more willing to participate in a depression inter-
vention, or more likely to be informed about specific
treatment programs for PDD. If so, then PDD patients
with lower education may be disadvantaged in this regard.
Moreover, findings from national health care data sug-
gest that the validity of medical depression diagnoses are
questionable, particularly in primary care [62], and that
improving treatment targeting [63, 64] and treatment
quality [19, 65–68] are desirable. In conclusion, these
findings highlight the need for national public health ini-
tiatives in Germany to reduce barriers to accessing men-
tal health care services in general and in individuals with
low education in particular, to strengthen awareness
using targeted information campaigns, and to improve
the quality of medical recognition and specialized treat-
ment provision for depression and its different courses.
There is thus a need to identify patients with PDD
correctly and to tailor specific treatment strategies.
Therefore, a focus on psychological characteristics [69,
70] is warranted, as the DSM-5 diagnosis of PDD is very
likely a heterogeneous umbrella diagnosis. For example,
different studies could differentiate PDD and non-PDD
in terms of psychopathological features and social func-
tioning (e.g., cognitive and affective reactivity [69, 70]
and interpersonal behavior [71]. This is important for
the development of new treatment approaches as well as
for the empirical corroboration and refinement of exist-
ing treatment attempts. For instance, CBASP was specif-
ically developed for the treatment of PDD [40]. CBASP
particularly considers psychopathological features of
PDD such as an early onset due to childhood maltreat-
ment and interpersonal withdrawal and avoidance. Evi-
dence for the effectiveness of CBASP is encouraging (e.g.
[72]), especially in patients with childhood maltreatment
[73]. There is also evidence that the improvement of
interpersonal behavior through CBASP is associated
with symptom reduction, thus providing an important
treatment target for PDD [74]. In this regard, CBASP
proved to be more effective than less specific psycho-
therapeutic treatments [75, 76].
Limitations
In interpreting the findings of this study some potential
limitations should be considered, such as the study de-
sign, response and reporting bias, and construct overlap.
The small number of PDD cases in both the clinical
sample and the DEGS1-MH sample may have reduced
the accuracy of the frequency and mean estimates. Thus,
significant differences between the samples may not
have been detected using non-overlapping 95% CI.
Comparisons between PDD cases of DEGS1-MH and
cases of the clinical sample are limited for several reasons.
Particularly severe and chronic depression cases may be
underrepresented in DEGS1-MH owing to the exclusion
of institutionalized subjects, selective non-responses of less
healthy individuals, and the inclusion of participants with
private health insurance as well as some longitudinal par-
ticipants (with a potentially greater probability of re-
participation among healthier persons) [33–35]. Moreover,
we found that clinical PDD patients had a higher educa-
tional level than DEGS1-MH participants. This also limits
the group comparison. However, it could indicate that pa-
tients with PDD and a higher educational level have easier
access to specified treatment programs. The comparison
between the DEGS1-MH and clinical samples is further
limited in terms of psychological comorbidity, owing to
the use of different diagnostic tools (CIDI vs. SCID I). Fur-
thermore, recall bias may have been more pronounced for
DEGS1-MH cases, since PDD was defined on the basis of
lifetime information, whereas the clinical sample only in-
cluded patients diagnosed by PDD within the last 6 years.
Thus, recall bias may have led to an underestimation of de-
pression characteristics particularly among DEGS1-MH
cases, e.g. with regard to treatment resistance and a history
of suicidality. Furthermore, recall bias, varying diagnostic
accuracy, and participants’ reporting bias may also have
led to the underestimation of comorbidity and chronic de-
pression course during the lifetime in both surveys, par-
ticularly among male and older participants [64, 77].
In DEGS1-MH, the small number of PDD and NCMDD
cases may also have led to low statistical power for detect-
ing the effects of depression course on health-related out-
comes. Furthermore, time lags between the core DEGS1
survey and its mental health supplement may have led to
an underestimation of associations between PDD/
NCMDD and health-related correlates, as well as differing
reference time frames for CIDI-based depression course
during the lifetime and outcome variables (e.g., health ser-
vice utilization during the past 12months). However, con-
struct overlap between depressive symptoms and the
examined outcome measures (e.g., SF-36 and limitation
days) may have led to the overestimation of associations.
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Conclusions
Finally, a chronic course of depression is challenging for
both patients and practitioners. However, a knowledge
gap remains regarding the lifetime characteristics and
correlates of chronic depression and the reliability of the
PDD concept itself.
By combining clinical and epidemiological perspectives,
our study permitted a comparison of standardized charac-
teristics of PDD among clinical vs. non-clinical cases and
therefore extends existing knowledge about PDD. Our
data suggest that the distinction between chronic and
non-chronic depression proposed for DSM-5, in the form
of PDD, is warranted. In particular, early onset depression,
attempted suicide, self-classification as persistent depres-
sive course, and treatment resistance are suggested as
markers of more severe and chronic depression courses.
Furthermore, health-related correlates of PDD vs. non-
chronic depression were compared at a population level.
Thus, the associated individual and economic disease bur-
den was evaluated for the general population in Germany
for the first time. At a population level, chronic depression
is associated with a remarkably higher disease burden than
non-chronic courses, indicating enormous direct and indir-
ect costs of chronic depression for the national economy
and emphasizing its public health relevancy. In conclusion,
these findings can inform the planning and targeting of
prevention and health services. They highlight the need to
further reduce barriers to accessing mental health care, im-
prove awareness of different depression courses among
health professionals, and implement specific treatment con-
cepts for chronic depression.
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